Zura Bio

Historical price data

Zura Bio is focused on creating transformative treatments for complex autoimmune diseases through a dual antagonism strategy, targeting multiple inflammatory pathways simultaneously to improve efficacy. Founded in 2022, the company has rapidly built a portfolio of three clinical-stage assets in-licensed from Pfizer and Eli Lilly, with its lead program in Phase 2 development. Zura Bio went public via a SPAC merger in 2023 and has since raised significant capital to advance its pipeline, positioning itself to address high unmet needs in conditions like systemic sclerosis.

Dual-pathway antagonism platform focused on developing bispecific antibodies that simultaneously target multiple immune pathways (e.g., T-cell and B-cell signaling) to treat complex autoimmune diseases.

2 drugs in pipeline

Total raised: $170M

Zura Bio competes with large pharma companies developing IL-17 inhibitors (Novartis, Eli Lilly, UCB) and BAFF inhibitors (GSK) in autoimmune diseases. Its key differentiation is the combination of these two mechanisms in a single molecule (tibulizumab), aiming for superior efficacy in complex diseases like systemic sclerosis where single-pathway therapies have shown limited success.